Curated News
By: NewsRamp Editorial Staff
April 22, 2025
Nutriband Secures New Trademark and Patents, Targets Lucrative Sales Opportunity
TLDR
- Nutriband secures new U.S. trademark and international patents for AVERSA(TM) platform, gaining market edge.
- Nutriband's AVERSA(TM) platform focuses on reducing abuse, diversion, and accidental exposure of potent drugs like Fentanyl.
- Nutriband's abuse-deterrent transdermal pharmaceuticals aim to make the world safer by preventing drug abuse and diversion.
- Strategic sports partnership with Charlotte FC enhances Nutriband's brand visibility, combining healthcare innovation with community engagement.
Impact - Why it Matters
This news highlights Nutriband's commitment to innovation and market growth in the pharmaceutical sector, particularly in the abuse-deterrent drug delivery space. The company's focus on intellectual property protection underscores its dedication to long-term success and market leadership. Investors and stakeholders should take note of Nutriband's strategic advancements and partnerships for potential future opportunities.
Summary
Nutriband secures new U.S. trademark and international patents for AVERSA(TM) platform, targeting a significant sales opportunity with its abuse-deterrent Fentanyl patch. Strategic sports partnership with Charlotte FC enhances brand visibility. The company continues to strengthen its intellectual property for long-term market protection, showcasing the importance of its AVERSA(TM) platform.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Nutriband Secures New Trademark and Patents, Targets Lucrative Sales Opportunity
